Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPD | P32754 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23762804 | 0.81 | ALDH1A1 (0.31) | LMNAALDH1A1MAPT | |
| SCHEMBL24952481 | 0.80 | KMT2A (0.34) | KMT2A | |
| SCHEMBL23762803 | 0.76 | — | — | |
| SCHEMBL14491564 | 0.71 | BRD4 (0.36) | BRD4LMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL19235507 | 0.71 | BRD4 (0.36) | BRD4LMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL18937487 | 0.70 | BRD4 (0.35) | BRD4LMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL9117924 | 0.69 | BRD4 (0.33) | BRD4LMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL24616657 | 0.68 | — | — | |
| SCHEMBL18937212 | 0.68 | L3MBTL1 (0.35) | BRD4LMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL7964135 | 0.68 | BRD4 (0.35) | BRD4LMNAALDH1A1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578069-B2 | Compounds for inhibition of α4 β7 integrin | GILEAD SCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210053967-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578069-B2 | Compounds for inhibition of α4 β7 integrin | ITGB7, ITGB4, ITGA4 | BRD4 1474/4885LMNA 3368/4885ALDH1A1 830/4885 |
| US-20210053967-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | BRD4 1725/4885LMNA 2467/4885ALDH1A1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.